Pfizer Reports Sutent Safe And Effective In Asians; Forges Alliances With Major Asian Oncology Centers
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Pfizer Sept. 21 released data on a Phase IIIb Asian trial of its leading oncology drug multi-kinase inhibitor Sutent, which demonstrated similar effectiveness and tolerability in Asians as in non-Asians
You may also be interested in...
Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval
The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid
Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval
The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid
As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
BEIJING - With the fate of a $68-billion merger with Wyeth now being reviewed by the Chinese leadership, Pfizer Chief Executive Officer Jeff Kindler is on a five-day, whirlwind tour of the country, in part to launch a new wave of partnerships with scientists and scholars